Background Primary (idiopathic) pulmonary hypertension is aprogressive, fatal disease. Conventional therapy with anticoagulantand vasodilator drugs may improve symptoms and survival amongselected patients, but there is no evidence that the diseasecan be reversed.
Methods We evaluated the effects of long-term therapy (i.e.,for more than one year) with intravenous epoprostenol (prostacyclin)in patients with advanced primary pulmonary hypertension. Thebase-line evaluation included an assessment of pulmonary vasculardilation in response to intravenous adenosine. The epoprostenoldose was increased monthly to the maximum tolerated. Long-termtherapy was evaluated by measuring improvement in symptoms,exercise capacity, and hemodynamic variables.
Results We evaluated 27 patients with primary pulmonary hypertensionover a mean (±SD) period of 16.7±5.2 months. Intravenousadenosine had a variable effect on pulmonary vascular resistance(mean reduction, 27 percent; range, 0 to 56; P<0.001). Epoprostenoltherapy was initiated and the rate of infusion was increasedby an average of 2.4 ng per kilogram of body weight per minuteeach month. Twenty-six of the 27 patients had improvement insymptoms and hemodynamic measures, and overall, pulmonary vascularresistance declined by 53 percent to 7.9±3.8 resistanceunits (P<0.001) at the time of restudy. The long-term effectsof epoprostenol exceeded the short-term pulmonary vasodilatorresponse to adenosine in all but one patient. Seven of the eightpatients who had minimal pulmonary vasodilation in responseto adenosine (mean reduction in resistance units, <20 percent)still had a significant reduction in pulmonary vascular resistancewhen treated with epoprostenol (mean, 39±14 percent;P = 0.002).
Conclusions In primary pulmonary hypertension, long-term therapywith epoprostenol lowers pulmonary vascular resistance beyondthe level achieved in the short term with intravenous adenosine.Epoprostenol appears to have sustained efficacy in this disorder.
Source Information
From the Section of Cardiology, Rush Medical College, Rush–Presbyterian–St. Luke's Medical Center, Chicago.
Address reprint requests to Dr. Rich at the Rush Heart Institute, Center for Pulmonary Heart Disease, Rush–Presbyterian–St. Luke's Medical Center, 1725 W. Harrison St., Suite 020, Chicago, IL 60612-3824.
Taichman, D. B.
(2008). Therapy for Pulmonary Arterial Hypertension: The More, the Merrier?. ANN INTERN MED
149: 583-585
[Full Text]
Boutet, K., Montani, D., Jais, X., Yaici, A., Sitbon, O., Simonneau, G., Humbert, M.
(2008). Review: Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis
2: 249-265
[Abstract]
Obata, H., Sakai, Y., Ohnishi, S., Takeshita, S., Mori, H., Kodama, M., Kangawa, K., Aizawa, Y., Nagaya, N.
(2008). Single Injection of a Sustained-release Prostacyclin Analog Improves Pulmonary Hypertension in Rats. Am. J. Respir. Crit. Care Med.
177: 195-201
[Abstract][Full Text]
Lang, I. M.
(2007). Management of acute and chronic RV dysfunction. Eur Heart J Suppl
9: H61-H67
[Abstract][Full Text]
Rubenfire, M., McLaughlin, V. V., Allen, R. P., Elliott, G., Park, M. H., Wade, M., Schilz, R.
(2007). Transition From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension: A Controlled Trial. Chest
132: 757-763
[Abstract][Full Text]
Takaoka, S., Faul, J. L., Doyle, R.
(2007). Current Therapies for Pulmonary Arterial Hypertension. SEMIN CARDIOTHORAC VASC ANESTH
11: 137-148
[Abstract]
Diller, G.-P., Gatzoulis, M. A.
(2007). Pulmonary Vascular Disease in Adults With Congenital Heart Disease. Circulation
115: 1039-1050
[Abstract][Full Text]
Williams, M H, Das, C, Handler, C E, Akram, M R, Davar, J, Denton, C P, Smith, C J, Black, C M, Coghlan, J G
(2006). Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart
92: 926-932
[Abstract][Full Text]
Tapson, V. F., Gomberg-Maitland, M., McLaughlin, V. V., Benza, R. L., Widlitz, A. C., Krichman, A., Barst, R. J.
(2006). Safety and Efficacy of IV Treprostinil for Pulmonary Arterial Hypertension: A Prospective, Multicenter, Open-Label, 12-Week Trial. Chest
129: 683-688
[Abstract][Full Text]
Gomberg-Maitland, M., Tapson, V. F., Benza, R. L., McLaughlin, V. V., Krichman, A., Widlitz, A. C., Barst, R. J.
(2005). Transition from Intravenous Epoprostenol to Intravenous Treprostinil in Pulmonary Hypertension. Am. J. Respir. Crit. Care Med.
172: 1586-1589
[Abstract][Full Text]
Kataoka, M., Nagaya, N., Satoh, T., Itoh, T., Murakami, S., Iwase, T., Miyahara, Y., Kyotani, S., Sakai, Y., Kangawa, K., Ogawa, S.
(2005). A Long-Acting Prostacyclin Agonist with Thromboxane Inhibitory Activity for Pulmonary Hypertension. Am. J. Respir. Crit. Care Med.
172: 1575-1580
[Abstract][Full Text]
Shen, J., He, B., Wang, B.
(2005). Effects of Lipo-Prostaglandin E1 on Pulmonary Hemodynamics and Clinical Outcomes in Patients With Pulmonary Arterial Hypertension. Chest
128: 714-719
[Abstract][Full Text]
Ford, K.
(2005). Pulmonary artery hypertension: new drug treatment in children. EDUCATION AND PRACTICE
90: ep15-ep20
[Full Text]
Bossone, E., Bodini, B. D., Mazza, A., Allegra, L.
(2005). Pulmonary Arterial Hypertension: The Key Role of Echocardiography. Chest
127: 1836-1843
[Abstract][Full Text]
Lee, A. J, Chiao, T. B, Tsang, M. P
(2005). Sildenafil for Pulmonary Hypertension. The Annals of Pharmacotherapy
39: 869-884
[Abstract][Full Text]
Higenbottam, T.
(2005). Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease: A Case for Treatment. Proc Am Thorac Soc
2: 12-19
[Abstract][Full Text]
Phillips, P. G., Long, L., Wilkins, M. R., Morrell, N. W.
(2005). cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am. J. Physiol. Lung Cell. Mol. Physiol.
288: L103-L115
[Abstract][Full Text]
Task Force members, , Galie, N., Torbicki, A., Barst, R., Dartevelle, P., Haworth, S., Higenbottam, T., Olschewski, H., Peacock, A., Pietra, G., Rubin, L. J., Simonneau, G.
(2004). Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J
25: 2243-2278
[Full Text]
Rodriguez-Roisin, R., Krowka, M.J., Herve, Ph., Fallon, M.B., on behalf of the ERS Task Force Pulmonary-Hepatic,
(2004). Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J
24: 861-880
[Full Text]
Langleben, D., Hirsch, A. M., Shalit, E., Lesenko, L., Barst, R. J.
(2004). Sustained Symptomatic, Functional, and Hemodynamic Benefit With the Selective Endothelin-A Receptor Antagonist, Sitaxsentan, in Patients With Pulmonary Arterial Hypertension: A 1-Year Follow-up Study. Chest
126: 1377-1381
[Abstract][Full Text]
Morimatsu, H., Goto, K., Matsusaki, T., Katayama, H., Matsubara, H., Ohe, T., Morita, K.
(2004). Rapid Development of Severe Interstitial Pneumonia Caused by Epoprostenol in a Patient with Primary Pulmonary Hypertension. Anesth. Analg.
99: 1205-1207
[Abstract][Full Text]
Tissieres, P., Nicod, L., Barazzone-Argiroffo, C., Rimensberger, P. C., Beghetti, M.
(2004). Aerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertension. Ann. Thorac. Surg.
78: e48-e50
[Abstract][Full Text]
Oudiz, R. J., Schilz, R. J., Barst, R. J., Galie, N., Rich, S., Rubin, L. J., Simonneau, G.
(2004). Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Chest
126: 420-427
[Abstract][Full Text]
Sobolewski, A., Jourdan, K. B., Upton, P. D., Long, L., Morrell, N. W.
(2004). Mechanism of cicaprost-induced desensitization in rat pulmonary artery smooth muscle cells involves a PKA-mediated inhibition of adenylyl cyclase. Am. J. Physiol. Lung Cell. Mol. Physiol.
287: L352-L359
[Abstract][Full Text]
Braun, E. B., Palin, C. A., Hogue, C. W.
(2004). Vasopressin During Spinal Anesthesia in a Patient with Primary Pulmonary Hypertension Treated with Intravenous Epoprostenol. Anesth. Analg.
99: 36-37
[Abstract][Full Text]
Badesch, D. B., Abman, S. H., Ahearn, G. S., Barst, R. J., McCrory, D. C., Simonneau, G., McLaughlin, V. V.
(2004). Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines. Chest
126: 35S-62S
[Abstract][Full Text]
Badesch, D. B., McLaughlin, V. V., Delcroix, M., Vizza, C., Olschewski, H., Sitbon, O., Barst, R. J.
(2004). Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol
43: 56S-61S
[Abstract][Full Text]
Elliott, C G, Palevsky, H I
(2004). Treatment with epoprostenol of pulmonary arterial hypertension following mitral valve replacement for mitral stenosis. Thorax
59: 536-537
[Abstract][Full Text]
Wade, M., Baker, F. J., Roscigno, R., DellaMaestra, W., Arneson, C. P., Hunt, T. L., Lai, A. A.
(2004). Pharmacokinetics of Treprostinil Sodium Administered by 28-Day Chronic Continuous Subcutaneous Infusion. J Clin Pharmacol
44: 503-509
[Abstract][Full Text]
Eells, P. L.
(2004). Advances in Prostacyclin Therapy for Pulmonary Arterial Hypertension. Crit Care Nurse
24: 42-54
[Full Text]
Wada, M., Yokoyama, C., Hatae, T., Shimonishi, M., Nakamura, M., Imai, Y., Ullrich, V., Tanabe, T.
(2004). Purification and Characterization of Recombinant Human Prostacyclin Synthase. J Biochem
135: 455-463
[Abstract][Full Text]
Leuchte, H. H., Schwaiblmair, M., Baumgartner, R. A., Neurohr, C. F., Kolbe, T., Behr, J.
(2004). Hemodynamic Response to Sildenafil, Nitric Oxide, and Iloprost in Primary Pulmonary Hypertension. Chest
125: 580-586
[Abstract][Full Text]
Matot, I., Gozal, Y.
(2004). Pulmonary Responses to Selective Phosphodiesterase-5 and Phosphodiesterase-3 Inhibitors. Chest
125: 644-651
[Abstract][Full Text]
Nagaya, N., Kyotani, S., Uematsu, M., Ueno, K., Oya, H., Nakanishi, N., Shirai, M., Mori, H., Miyatake, K., Kangawa, K.
(2004). Effects of Adrenomedullin Inhalation on Hemodynamics and Exercise Capacity in Patients With Idiopathic Pulmonary Arterial Hypertension. Circulation
109: 351-356
[Abstract][Full Text]
Budhiraja, R., Tuder, R. M., Hassoun, P. M.
(2004). Endothelial Dysfunction in Pulmonary Hypertension. Circulation
109: 159-165
[Full Text]
Wade, M., Baker, F. J., Roscigno, R., DellaMaestra, W., Hunt, T. L., Lai, A. A.
(2004). Absolute Bioavailability and Pharmacokinetics of Treprostinil Sodium Administered by Acute Subcutaneous Infusion. J Clin Pharmacol
44: 83-88
[Abstract][Full Text]
Hironaka, E., Hongo, M., Sakai, A., Mawatari, E., Terasawa, F., Okumura, N., Yamazaki, A., Ushiyama, Y., Yazaki, Y., Kinoshita, O.
(2003). Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res
60: 692-699
[Abstract][Full Text]
Lau, C.L., Patterson, G.A.
(2003). Current status of lung transplantation. Eur Respir J
22: 57s-64s
[Abstract][Full Text]
Nagaya, N., Okumura, H., Uematsu, M., Shimizu, W., Ono, F., Shirai, M., Mori, H., Miyatake, K., Kangawa, K.
(2003). Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats. Am. J. Physiol. Heart Circ. Physiol.
285: H2125-H2131
[Abstract][Full Text]
Mukerjee, D, St George, D, Coleiro, B, Knight, C, Denton, C P, Davar, J, Black, C M, Coghlan, J G
(2003). Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis
62: 1088-1093
[Abstract][Full Text]
Kim, N. H., Channick, R. N., Rubin, L. J.
(2003). Successful Withdrawal of Long-term Epoprostenol Therapy for Pulmonary Arterial Hypertension. Chest
124: 1612-1615
[Abstract][Full Text]
Hoeper, M.M., Taha, N., Bekjarova, A., Gatzke, R., Spiekerkoetter, E.
(2003). Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J
22: 330-334
[Abstract][Full Text]
Sharma, S.
(2003). Treatment of Pulmonary Arterial Hypertension: A Step Forward. Chest
124: 8-11
[Full Text]
Sitbon, O., Badesch, D. B., Channick, R. N., Frost, A., Robbins, I. M., Simonneau, G., Tapson, V. F., Rubin, L. J.
(2003). Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial Hypertension: A 1-Year Follow-up Study. Chest
124: 247-254
[Abstract][Full Text]
Barst, R. J., McGoon, M., McLaughlin, V., Tapson, V., Oudiz, R., Shapiro, S., Robbins, I. M., Channick, R., Badesch, D., Rayburn, B. K., Flinchbaugh, R., Sigman, J., Arneson, C., Jeffs, R., Beraprost Study Group,
(2003). Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol
41: 2119-2125
[Abstract][Full Text]
Nunes, H., Humbert, M., Sitbon, O., Morse, J. H., Deng, Z., Knowles, J. A., Le Gall, C., Parent, F., Garcia, G., Herve, P., Barst, R. J., Simonneau, G.
(2003). Prognostic Factors for Survival in Human Immunodeficiency Virus-associated Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med.
167: 1433-1439
[Abstract][Full Text]
Ono, F., Nagaya, N., Okumura, H., Shimizu, Y., Kyotani, S., Nakanishi, N., Miyatake, K.
(2003). Effect of Orally Active Prostacyclin Analogue on Survival in Patients With Chronic Thromboembolic Pulmonary Hypertension Without Major Vessel Obstruction. Chest
123: 1583-1588
[Abstract][Full Text]
Peacock, A. J
(2003). Treatment of pulmonary hypertension. BMJ
326: 835-836
[Full Text]
Moloney, E.D., Evans, T.W.
(2003). Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome. Eur Respir J
21: 720-727
[Abstract][Full Text]
Stiebellehner, L., Petkov, V., Vonbank, K., Funk, G., Schenk, P., Ziesche, R., Block, L.-H.
(2003). Long-term Treatment With Oral Sildenafil in Addition to Continuous IV Epoprostenol in Patients With Pulmonary Arterial Hypertension. Chest
123: 1293-1295
[Abstract][Full Text]
Rodes-Cabau, J, Domingo, E, Roman, A, Majo, J, Lara, B, Padilla, F, Anivarro, I, Angel, J, Tardif, J C, Soler-Soler, J
(2003). Intravascular ultrasound of the elastic pulmonary arteries: a new approach for the evaluation of primary pulmonary hypertension. Heart
89: 311-315
[Abstract][Full Text]
Kuhn, K. P., Byrne, D. W., Arbogast, P. G., Doyle, T. P., Loyd, J. E., Robbins, I. M.
(2003). Outcome in 91 Consecutive Patients with Pulmonary Arterial Hypertension Receiving Epoprostenol. Am. J. Respir. Crit. Care Med.
167: 580-586
[Abstract][Full Text]
Gibbs, J.S. R, Wharton, J., Wilkins, M. R
(2003). Pulmonary arterial hypertension and the vasoconstrictive factor: is there still a role for vasodilator testing?. Eur Heart J
24: 297-298
[Full Text]
Opitz, C.F, Wensel, R, Bettmann, M, Schaffarczyk, R, Linscheid, M, Hetzer, R, Ewert, R
(2003). Assessment of the vasodilator response in primary pulmonary hypertension: Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J
24: 356-365
[Abstract][Full Text]
Nagaya, N., Sasaki, N., Ando, M., Ogino, H., Sakamaki, F., Kyotani, S., Nakanishi, N.
(2003). Prostacyclin Therapy Before Pulmonary Thromboendarterectomy in Patients With Chronic Thromboembolic Pulmonary Hypertension. Chest
123: 338-343
[Abstract][Full Text]
Widlitz, A., Barst, R.J.
(2003). Pulmonary arterial hypertension in children. Eur Respir J
21: 155-176
[Abstract][Full Text]
Chemla, D., Castelain, V., Herve, P., Lecarpentier, Y., Brimioulle, S.
(2002). Haemodynamic evaluation of pulmonary hypertension. Eur Respir J
20: 1314-1331
[Abstract][Full Text]
Wort, S. J., Woods, M., Warner, T. D., Evans, T. W., Mitchell, J. A.
(2002). Cyclooxygenase-2 Acts as an Endogenous Brake on Endothelin-1 Release by Human Pulmonary Artery Smooth Muscle Cells: Implications for Pulmonary Hypertension. Mol. Pharmacol.
62: 1147-1153
[Abstract][Full Text]
Yokoyama, C., Yabuki, T., Shimonishi, M., Wada, M., Hatae, T., Ohkawara, S., Takeda, J., Kinoshita, T., Okabe, M., Tanabe, T.
(2002). Prostacyclin-Deficient Mice Develop Ischemic Renal Disorders, Including Nephrosclerosis and Renal Infarction. Circulation
106: 2397-2403
[Abstract][Full Text]
Bradbury, D. A., Newton, R., Zhu, Y.-M., Stocks, J., Corbett, L., Holland, E. D., Pang, L. H., Knox, A. J.
(2002). Effect of bradykinin, TGF-beta 1, IL-1beta , and hypoxia on COX-2 expression in pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol.
283: L717-L725
[Abstract][Full Text]
Chatterjee, K., De Marco, T., Alpert, J. S.
(2002). Pulmonary Hypertension: Hemodynamic Diagnosis and Management. Arch Intern Med
162: 1925-1933
[Abstract][Full Text]
McLaughlin, V. V., Shillington, A., Rich, S.
(2002). Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy. Circulation
106: 1477-1482
[Abstract][Full Text]
Raychaudhuri, B., Malur, A., Bonfield, T. L., Abraham, S., Schilz, R. J., Farver, C. F., Kavuru, M. S., Arroliga, A. C., Thomassen, M. J.
(2002). The Prostacyclin Analogue Treprostinil Blocks NFkappa B Nuclear Translocation in Human Alveolar Macrophages. J. Biol. Chem.
277: 33344-33348
[Abstract][Full Text]
Sitbon, O., Humbert, M., Nunes, H., Parent, F., Garcia, G., Herve, P., Rainisio, M., Simonneau, G.e.
(2002). Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol
40: 780-788
[Abstract][Full Text]
Hoeper, M.M., Spiekerkoetter, E., Westerkamp, V., Gatzke, R., Fabel, H.
(2002). Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. Eur Respir J
20: 339-343
[Abstract][Full Text]
Olschewski, H., Simonneau, G., Galie, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., Winkler, J., Sitbon, O., Popov, W., Ghofrani, H. A., Manes, A., Kiely, D. G., Ewert, R., Meyer, A., Corris, P. A., Delcroix, M., Gomez-Sanchez, M., Siedentop, H., Seeger, W., the Aerosolized Iloprost Randomized Study Group,
(2002). Inhaled Iloprost for Severe Pulmonary Hypertension. NEJM
347: 322-329
[Abstract][Full Text]
Ueno, M., Miyauchi, T., Sakai, S., Yamauchi-Kohno, R., Goto, K., Yamaguchi, I.
(2002). A combination of oral endothelin-areceptor antagonist and oral prostacyclinanalogue is superior to each drug alone inameliorating pulmonary hypertension in rats. J Am Coll Cardiol
40: 175-181
[Abstract][Full Text]
Evans, T W, Gatzoulis, M A, Gibbs, J S R
(2002). A National Pulmonary Hypertension Service for England & Wales: an orphan disease is adopted?. Thorax
57: 471-472
[Full Text]
Vachiery, J.-L., Hill, N., Zwicke, D., Barst, R., Blackburn, S., Naeije, R.
(2002). Transitioning From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension*. Chest
121: 1561-1565
[Abstract][Full Text]
Blumberg, F. C., Riegger, G. A. J., Pfeifer, M.
(2002). Hemodynamic Effects of Aerosolized Iloprost in Pulmonary Hypertension at Rest and During Exercise*. Chest
121: 1566-1571
[Abstract][Full Text]
Hoeper, M. M., Galie, N., Simonneau, G., Rubin, L. J.
(2002). New Treatments for Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med.
165: 1209-1216
[Full Text]
Nagaya, N, Shimizu, Y, Satoh, T, Oya, H, Uematsu, M, Kyotani, S, Sakamaki, F, Sato, N, Nakanishi, N, Miyatake, K
(2002). Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension. Heart
87: 340-345
[Abstract][Full Text]
SIMONNEAU, G., BARST, R. J., GALIE, N., NAEIJE, R., RICH, S., BOURGE, R. C., KEOGH, A., OUDIZ, R., FROST, A., BLACKBURN, S. D., CROW, J. W., RUBIN, L. J.
(2002). Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension . A Double-blind, Randomized, Placebo-controlled Trial. Am. J. Respir. Crit. Care Med.
165: 800-804
[Abstract][Full Text]
Beghetti, M., Reber, G., de Moerloose, P., Vadas, L., Chiappe, A., Spahr-Schopfer, I., Rimensberger, P.C.
(2002). Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur Respir J
19: 518-524
[Abstract][Full Text]
Tuder, R. M., Zaiman, A. L.
(2002). Prostacyclin Analogs as the Brakes for Pulmonary Artery Smooth Muscle Cell Proliferation . Is It Sufficient to Treat Severe Pulmonary Hypertension?. Am. J. Respir. Cell Mol. Bio.
26: 171-174
[Full Text]
CASTELAIN, V., CHEMLA, D., HUMBERT, M., SITBON, O., SIMONNEAU, G., LECARPENTIER, Y., HERVE, P.
(2002). Pulmonary Artery Pressure-Flow Relations after Prostacyclin in Primary Pulmonary Hypertension. Am. J. Respir. Crit. Care Med.
165: 338-340
[Abstract][Full Text]
DAVIE, N., HALEEN, S. J., UPTON, P. D., POLAK, J. M., YACOUB, M. H., MORRELL, N. W., WHARTON, J.
(2002). ETA and ETB Receptors Modulate the Proliferation of Human Pulmonary Artery Smooth Muscle Cells. Am. J. Respir. Crit. Care Med.
165: 398-405
[Abstract][Full Text]
Mendeloff, E. N., Meyers, B. F., Sundt, T. M., Guthrie, T. J., Sweet, S. C., de la Morena, M., Shapiro, S., Balzer, D. T., Trulock, E. P., Lynch, J. P., Pasque, M. K., Cooper, J. D., Huddleston, C. B., Patterson, G. A.
(2002). Lung transplantation for pulmonary vascular disease. Ann. Thorac. Surg.
73: 209-219
[Abstract][Full Text]
Haft, J. W., Montoya, P., Alnajjar, O., Posner, S. R., Bull, J. L., Iannettoni, M. D., Bartlett, R. H., Hirschl, R. B.
(2001). An artificial lung reduces pulmonary impedance and improves right ventricular efficiency in pulmonary hypertension. J. Thorac. Cardiovasc. Surg.
122: 1094-1100
[Abstract][Full Text]
WILKINS, M. R, WHARTON, J.
(2001). Progress in, and future prospects for, the treatment of primary pulmonary hypertension. Heart
86: 603-604
[Full Text]
Vizza, C D, Sciomer, S, Morelli, S, Lavalle, C, Di Marzio, P, Padovani, D, Badagliacca, R, Vestri, A R, Naeije, R, Fedele, F
(2001). Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart
86: 661-665
[Abstract][Full Text]
SCHERMULY, R. T., KRUPNIK, E., TENOR, H., SCHUDT, C., WEISSMANN, N., ROSE, F., GRIMMINGER, F., SEEGER, W., WALMRATH, D., GHOFRANI, H. A.
(2001). Coaerosolization of Phosphodiesterase Inhibitors Markedly Enhances the Pulmonary Vasodilatory Response to Inhaled Iloprost in Experimental Pulmonary Hypertension . Maintenance of Lung Selectivity. Am. J. Respir. Crit. Care Med.
164: 1694-1700
[Abstract][Full Text]
Greidinger, E. L., Gaine, S. P., Wise, R. A., Boling, C., Housten-Harris, T., Wigley, F. M.
(2001). Primary Pulmonary Hypertension Is Not Associated With Scleroderma-Like Changes in Nailfold Capillaries. Chest
120: 796-800
[Abstract][Full Text]
Preston, I. R., Klinger, J. R., Landzberg, M. J., Houtchens, J., Nelson, D., Hill, N. S.
(2001). Vasoresponsiveness of Sarcoidosis-Associated Pulmonary Hypertension. Chest
120: 866-872
[Abstract][Full Text]
Beghetti, M, Berner, M, Rimensberger, P C
(2001). Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion. Heart
86: e10-10
[Abstract][Full Text]
British Cardiac Society Guidelines and Medical Pra,
(2001). Recommendations on the management of pulmonary hypertension in clinical practice. Heart
86: i1-13
[Full Text]
HOSHIKAWA, Y., VOELKEL, N. F., GESELL, T. L., MOORE, M. D., MORRIS, K. G., ALGER, L. A., NARUMIYA, S., GERACI, M. W.
(2001). Prostacyclin Receptor-dependent Modulation of Pulmonary Vascular Remodeling. Am. J. Respir. Crit. Care Med.
164: 314-318
[Abstract][Full Text]
Wort, S. J., Woods, M., Warner, T. D., Evans, T. W., Mitchell, J. A.
(2001). Endogenously Released Endothelin-1 from Human Pulmonary Artery Smooth Muscle Promotes Cellular Proliferation . Relevance to Pathogenesis of Pulmonary Hypertension and Vascular Remodeling. Am. J. Respir. Cell Mol. Bio.
25: 104-110
[Abstract][Full Text]
(2001). HIV-Associated Pulmonary Hypertension. AIDS Clin Care
2001: 6-6
[Full Text]
Geraci, M. W., Moore, M., Gesell, T., Yeager, M. E., Alger, L., Golpon, H., Gao, B., Loyd, J. E., Tuder, R. M., Voelkel, N. F.
(2001). Gene Expression Patterns in the Lungs of Patients With Primary Pulmonary Hypertension : A Gene Microarray Analysis. Circ. Res.
88: 555-562
[Abstract][Full Text]
Ting, H., Sun, X.-G., Chuang, M.-L., Lewis, D. A., Hansen, J. E., Wasserman, K.
(2001). A Noninvasive Assessment of Pulmonary Perfusion Abnormality in Patients With Primary Pulmonary Hypertension. Chest
119: 824-832
[Abstract][Full Text]
Perez-Penate, G., Julia-Serda, G., Pulido-Duque, J. M., Gorriz-Gomez, E., Cabrera-Navarro, P.
(2001). One-Year Continuous Inhaled Nitric Oxide for Primary Pulmonary Hypertension. Chest
119: 970-973
[Abstract][Full Text]
Stewart, R., Tuazon, D., Olson, G., Duarte, A. G.
(2001). Pregnancy and Primary Pulmonary Hypertension : Successful Outcome With Epoprostenol Therapy. Chest
119: 973-975
[Abstract][Full Text]
Machherndl, S., Kneussl, M., Baumgartner, H., Schneider, B., Petkov, V., Schenk, P., Lang, I.M.
(2001). Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur Respir J
17: 8-13
[Abstract][Full Text]
